A recently described knockout mouse has abnormally large muscles. The phenotype suggests that the ablated product, growth differentiation factor 8 or 'myostatin', may be one of the long sought inhibitors that control the growth of individual tissues and organs.
The problem of the control of growth is one of the last unsolved mysteries of animal development. It is rarely perceived as a problem, because much of the excitement of the last 15 years has been concerned with the mechanisms of regional specification in early embryos. During this period, it has been usual to dismiss growth as 'merely' the increase in the size of structures that were laid down in miniature at an early stage of development. But it is precisely because the early rudiments of body parts are very small, and the adult size is very big, that a real problem emerges: the slightest error in the factor of expansion of one body part relative to the others would create a serious disproportion. So how is the growth of the different body parts coordinated so that they produce a harmonious whole?
This question has exercised numerous thinkers over the years and an idea that keeps on surfacing is that of the circulating tissue-specific growth inhibitor [1] . This is an idea so elegant that it seems to compel belief despite a certain shortage of evidence in its favour. But a recent paper reporting the phenotype of a 'knockout' mouse with a targeted mutation in the gene encoding growth differentiation factor 8 -'myostatin' -may provide just such evidence [2] . These mice have muscles almost twice the size of their wild-type littermates -indicating that they lack a crucial growth inhibitor.
The proposition is that each tissue produces an inhibitor, and the total output of inhibitor from the tissue is proportional to its volume. The inhibitor diffuses freely and is removed by degradation which takes place all over the body. As it is produced by the specific tissue and is removed by the whole body, the steady-state concentration of the inhibitor provides a measure of the volume of the tissue relative to the volume of the whole body. Too little tissue and the inhibitor is in deficit, so the growth rate increases. Too much tissue and the inhibitor is in excess, so no more growth occurs until the whole body can catch up (Figure 1a,b) .
The critical predictions of this model relate to the behaviour of grafts of small organs into large hosts or vice versa. In principle, a small, or young, graft inserted into a full grown host, in place of the corresponding host organ (Figure 1d ), should rapidly expand to normal adult size. By contrast, if such a graft is added to, rather than replacing, the host organ (Figure 1f ), then its growth should be suppressed. Likewise, an adult organ grafted into a young host should not grow ( Figure 1c ) and should be able to suppress the continued growth of an endogenous organ of the same type (Figure 1e ). Unfortunately the data from tissue grafting is often inconclusive, as even in syngeneic animals the growth of a graft can be greatly dependent on vascularisation and other nutritional problems. Furthermore, much of the existing data were gathered before immune rejection was properly understood, so this too is often a complicating factor. The specific feedback inhibition model. (a,b) In normal animals, the level of inhibition keeps the tissue volume a constant proportion of the whole body. (c,e) Large grafts to small animals cause the level of inhibitor to accumulate and to prevent growth of the tissue. (d) A small replacement graft in a large host. Here, the inhibitor is at a low steady-state level and the graft will grow rapidly. (f) A small additional graft in a large host. Here, the inhibitor is at slightly above normal levels due to the augmentation of the tissue and so the graft should grow a little slower than the animal. Tissue is shown in green and inhibitor in purple. What results there are suggest that the systemic inhibition model may apply in certain cases but not in all. A contrary example is provided by careful studies, carried out in the 1920s, of transplanted eyes between large and small species of salamander. These revealed complete donor autonomy, suggesting that there is no systemic control except for an effect of the general nutritional state of the host [3, 4] . For the organs that do seem to follow the model to some extent, probably the best studied example is the liver [5] . It is well known that removal of part of the liver causes rapid compensatory growth of the remainder. The effect must be due to some substance in the blood, as it can be transmitted between animals whose circulations have been joined. The effects of transplantation also follow the model for those graft combinations that have been investigated. When a small liver is transplanted to a large host, then it will grow much faster than the normal rate until it has gained a size proportional to the host. Conversely, if a large liver is grafted to a small host, then its growth is suspended until the whole animal has caught up [6] .
Another case where there is at least some systemic growth control is the kidney. Removal of one kidney causes rapid hypertrophy of the other. Some of the graft combinations have been examined in the context of human organ transplantation. A child's kidney grafted into an adult grows quickly, while an adult's kidney grafted into a child remains the same size. Restoration of a kidney that was previously removed causes shrinkage of the contralateral hypertrophic kidney back to normal size. However, the addition of a third kidney cannot shrink the other two below the normal size, so it seems that hypertrophic growth can be shrunk more readily than can normal growth [7] .
What is actually happening when an organ grows? There may be an increase in cell size, or in cell number, or in the number of structural-proliferative tissue units -for example, the lobules of the liver or the nephrons of the kidney -or in extracellular material and tissue fluid. Any particular example of size change will show a combination of these processes. The control of cell size is very poorly understood, and what is known is mainly in the context of metabolic events such as fat deposition. A factor that is known to correlate closely to overall size is ploidy, with an approximate doubling of cell size for each doubling of chromosome complement. Polyploid cells do exist in the liver and account for some increase in cell size, but it seems most unlikely that all changes in cell size are due to polyploidy [8] .
The control of cell division is understood rather well in terms of the molecular biology of the cell cycle, or the action of growth factors on tissue culture cells, but it is not well understood in vivo. There is certainly very active cell division in the regenerating liver or hypertrophic kidney, and in the case of the liver it seems clear that circulating hepatocyte growth factor is an important mitogenic stimulus. The number of proliferative units is usually thought to stay the same during hypertrophic growth of the liver or kidney, but it has been shown that kidneys can increase their nephron number if the other kidney is removed during the normal period of nephron increase, which is about the first 50 days after birth in the case of rats [9] .
In no case is the identity of the putative tissue-specific inhibitors known. It has never really been clearly established to what extent the systemic regulators are specific growth factors and to what extent they are normal metabolites whose concentration depends on the organ size. It seems well established that hepatocyte growth factor is an important factor stimulating cell division in the regenerating liver, but its source lies outside the liver, and the identity of the signal from the liver that initially activates its expression and release is still not known.
So is myostatin a good candidate for a tissue-specific inhibitor? The sequence of this protein, a novel member of the transforming growth factor ␤ superfamily of growth factors, is reported in the same paper as the targeted mutation of the gene in mouse [2] . The gene is active from embryonic day 9.5, and is expressed mainly in the developing myotomes. Expression continues as the skeletal muscle differentiates and persists into post-natal life. At present, there is no information about the biological activity of myostatin from tissue culture or other in vitro systems, so the functional information comes just from the phenotype of the knockout mouse. The mutant mice are about 30% larger than wild-type or heterozygous litter mates, and this difference is entirely due to a substantial increase (approximately doubling) in the weight of skeletal muscle. The DNA content of the enlarged muscles is increased showing that the increased size is partly due to an increase in the number of nuclei, and hence in the number of myoblasts contributing to the muscle fibres. There is also some increase in fibre size as measured both from observations of fibre diameter and as deduced from the protein:DNA ratio.
To appreciate the significance of these results, it is worth briefly reviewing the normal mode of development of skeletal muscle [10] . In the embryo, myoblasts are formed from the myotomes of the somites. Some of these differentiate in situ, whereas others migrate into the limbs, body wall and other regions. Myoblasts proliferate for a while and then fuse with one another to form the multinucleate fibres characteristic of skeletal muscle. After fusion, neither the fibres nor the nuclei within them can divide any further. During the growth of the animal, however, there is an increase in the number of fibres per muscle. These derive from a population of mononucleate 'satellite cells', presumably derived from the embryonic myoblasts, that persists into adult life. During growth, the neither the fibres nor the nuclei within them can divide any further. During the growth of the animal, however, there is an increase in the number of fibres per muscle. These derive from a population of mononucleate 'satellite cells', presumably derived from the embryonic myoblasts, that persists into adult life. During growth, the satellite cells continue to divide and to form new myotubes, accounting for the increase in the number of fibres [11] . After cessation of whole animal growth, some satellite cells persist and are responsible for muscle regeneration following tissue damage. During normal growth, in addition to the formation of new fibres, there is also a considerable enlargement of existing fibres, without any increase in the number of nuclei. The increase in muscle size that can be achieved by exercise is also entirely due to an increase in fibre size, not to an increase in cell division or fibre number.
From the phenotype of the knockout mouse, we can deduce that myostatin normally operates as some sort of inhibitor, and that it probably represses both the number of myoblast divisions and, to some extent, the degree of fibre enlargement. The identification of a molecule that definitely affects cell division in vivo is interesting. Even more significant is the effect on cell size, as the control of cell size is not understood at all, and this may represent a tool for commencing some novel experimental studies. Most exciting of all would be a potential role for myostatin as a systemic inhibitor responsible for regulating the proportion of muscle in the body, following the specific feedback inhibition model. The first step in investigating this would be to find whether it circulates in the blood, and whether production of myostatin by one muscle can affect growth in another. If myostatin is a circulating systemic inhibitor then its discovery will represent a real molecular breakthrough into the problem of growth control, and future studies could open up one of the darkest and most mystifying corners of developmental biology.
